Education
About Us
Working with TipRanks
Follow Us
Hypera SA (HYPMY)
OTHER OTC:HYPMY
Top Page
Hypera SA
(OTC:HYPMY)
Select Model
Select Model
Rating:74Outperform
Price Target:
$5.50
▲(27.61% Upside)
Hypera SA's strong cash flow generation and strategic initiatives, as highlighted in the earnings call, are the most significant strengths. The technical indicators show positive momentum, although the stock is nearing overbought territory. Valuation metrics suggest the stock is fairly valued, with an attractive dividend yield. The main risks include declining profit margins and challenges in the institutional market.
Positive Factors
Strong Revenue Growth
The 16% revenue growth reflects Hypera's effective market strategies and robust product demand, indicating a strong market position and potential for sustained growth.
Operational Cash Flow
Record operational cash flow enhances liquidity and financial flexibility, supporting future investments and reducing financial risk.
High EBITDA Margin
A high EBITDA margin of 34% underscores Hypera's operational efficiency and ability to maintain profitability, even with revenue fluctuations.
Negative Factors
Decline in Institutional Market Sales
A 4% decline in institutional market sales could signal challenges in this segment, potentially impacting overall revenue diversification and stability.
R&D and Innovation Challenges
Delays in regulatory approvals can hinder new product launches, affecting Hypera's ability to innovate and compete effectively in the market.
Higher Discounts Impact
Increased discounts, particularly in generics, can pressure margins and reduce profitability, challenging Hypera's pricing strategy.
Hypera SA (HYPMY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.03B
Dividend Yield4.73%
Average Volume (3M)110.00
Price to Earnings (P/E)20.4
Beta (1Y)0.69
Revenue Growth-18.21%
EPS Growth-50.94%
CountryUS
Employees10,481
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.13
Shares Outstanding633,420,840
10 Day Avg. Volume0
30 Day Avg. Volume110
Financial Highlights & Ratios
PEG Ratio-0.50
Price to Book (P/B)0.99
Price to Sales (P/S)1.61
P/FCF Ratio6.79
Enterprise Value/Market Cap7.82
Enterprise Value/Revenue3.40
Enterprise Value/Gross Profit6.07
Enterprise Value/Ebitda14.69
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Hypera SA Business Overview & Revenue Model
Company DescriptionHypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. is based in São Paulo, Brazil.
How the Company Makes MoneyHypera SA generates revenue primarily through the sale of its pharmaceutical products, which includes prescription medications and over-the-counter drugs. The company has a diversified revenue model that includes direct sales through pharmacies, hospitals, and retail channels. Key revenue streams come from its established product lines in prescription pharmaceuticals, which are often supported by healthcare professionals and insurance reimbursements. Additionally, Hypera SA benefits from its consumer health segment, which includes well-known brands in personal care and health supplements. Strategic partnerships with healthcare providers and distribution networks enhance its market reach. The company also invests in research and development to innovate and expand its product offerings, contributing to sustained revenue growth.
Hypera SA Earnings Call Summary
Earnings Call Date:Oct 28, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Mar 12, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant achievements, including strong revenue growth, successful working capital optimization, and record operational cash flow. However, challenges were noted in the institutional market and R&D approval delays. Despite these challenges, the overall performance and strategic initiatives indicate a positive outlook.Q3-2025 Updates
Positive Updates
Successful Working Capital Optimization
The company successfully concluded its working capital optimization process, leading to improved operational cash generation without impacting sell-out or profitability.
Strong Revenue Growth
Net revenue increased by 16% to BRL 2.2 billion, driven by sell-out growth in retail, despite a 4% reduction in the institutional market.
High EBITDA Margin
Maintained an operational EBITDA margin of 34%, reaching nearly BRL 760 million, which is higher than previous quarters.
Record Operational Cash Flow
Achieved the highest operational cash flow in the company's history, with total cash generation of BRL 630 million, reducing net debt to 2.4x annualized EBITDA.
Strategic Product Launches
Focused on new product launches and market share gains, particularly in influenza medication, pain killers, gastric, cardiology, skin care, and hydration.
Negative Updates
Decline in Institutional Market Sales
Net revenue from the institutional market decreased by 4% due to a lower level of sales to the public market.
R&D and Innovation Challenges
Encountered delays in ANVISA approval times, impacting the pipeline for new product launches.
Higher Discounts Impact
Observed an increase in discounts due to a variation in the product mix, particularly higher sales in generics and similars.
Company Guidance
In the third quarter of 2025, Hypera Pharma demonstrated strong financial and operational performance, driven by strategic initiatives and market dynamics. The company successfully completed its working capital optimization process, which led to a significant improvement in operational cash generation without affecting sell-out or profitability. Sell-out increased by nearly 2 percentage points above the market and 3 percentage points above the growth in the second quarter, with particular strength in influenza medication, pain killers, and skincare products. Hypera maintained its operational profitability with an EBITDA of approximately BRL 760 million and a 34% margin, which was an improvement over previous quarters. Net revenue grew by 16% to BRL 2.2 billion, despite a 4% reduction in the institutional market, attributed to lower public market sales. The company's gross margins stood at 61.2%, and they reported a reduced investment in working capital, which now represents 30% of net revenue, down from previous years. Hypera also approved BRL 185 million in shareholder payments and strengthened its corporate governance. Looking ahead, the company plans to leverage its strong brand portfolio and innovation pipeline, with significant opportunities expected from the expiration of the semaglutide patent and other molecules.Hypera SA Financial Statement Overview
Summary
Hypera SA demonstrates strong cash flow generation and a stable balance sheet with improved leverage. However, declining profit margins and return on equity suggest potential challenges in maintaining profitability. The company is well-positioned in terms of cash flow, but needs to address profitability pressures to sustain long-term growth.Income Statement
Hypera SA shows a stable revenue growth trajectory with a 4.67% increase in TTM. The gross profit margin is healthy at 55.99%, although it has decreased from previous years. The net profit margin has also seen a decline to 11.82% in TTM, indicating some pressure on profitability. EBIT and EBITDA margins are strong, but have decreased compared to prior periods, suggesting potential cost pressures or increased competition.75
Positive
Balance Sheet
The company's debt-to-equity ratio has improved to 0.76 in TTM, indicating better leverage management compared to previous years. However, the return on equity has decreased to 6.85%, reflecting reduced profitability. The equity ratio remains stable, showing a solid capital structure, but the declining ROE is a concern for long-term profitability.70
Positive
Cash Flow
Hypera SA's free cash flow growth is impressive at 138.9% in TTM, indicating strong cash generation capabilities. The operating cash flow to net income ratio is moderate at 0.48, suggesting efficient cash conversion. The free cash flow to net income ratio is robust at 66.19%, highlighting strong cash flow relative to earnings.80
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.97B | 7.44B | 7.91B | 7.55B | 5.94B | 4.09B |
| Gross Profit | 3.90B | 4.38B | 5.00B | 4.76B | 3.80B | 2.63B |
| EBITDA | 1.61B | 2.23B | 2.88B | 2.77B | 2.16B | 1.42B |
| Net Income | 823.94M | 1.34B | 1.65B | 1.70B | 1.33B | 1.30B |
Balance Sheet | ||||||
| Total Assets | 28.53B | 24.56B | 24.51B | 23.76B | 19.82B | 17.25B |
| Cash, Cash Equivalents and Short-Term Investments | 1.86B | 1.74B | 2.58B | 2.86B | 2.29B | 4.74B |
| Total Debt | 9.33B | 9.40B | 9.96B | 9.68B | 7.41B | 5.59B |
| Total Liabilities | 16.27B | 12.46B | 12.99B | 13.10B | 9.98B | 8.01B |
| Stockholders Equity | 12.25B | 12.10B | 11.50B | 10.65B | 9.83B | 9.24B |
Cash Flow | ||||||
| Free Cash Flow | 1.58B | 1.77B | 1.58B | 529.34M | 560.25M | -744.16M |
| Operating Cash Flow | 2.39B | 2.54B | 2.40B | 2.04B | 1.40B | 1.18B |
| Investing Cash Flow | -750.02M | -592.44M | -791.19M | -1.74B | -4.41B | -1.90B |
| Financing Cash Flow | -2.99B | -2.79B | -1.89B | 278.95M | 557.06M | 3.21B |
Hypera SA Technical Analysis
Positive
4.31
Price Trends
4.51
Positive
4.43
Positive
4.41
Positive
Market Momentum
0.14
Negative
62.09
Neutral
65.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYPMY, the sentiment is Positive. The current price of 4.31 is below the 20-day moving average (MA) of 4.58, below the 50-day MA of 4.51, and below the 200-day MA of 4.41, indicating a bullish trend. The MACD of 0.14 indicates Negative momentum. The RSI at 62.09 is Neutral, neither overbought nor oversold. The STOCH value of 65.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HYPMY.
Hypera SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $3.03B | 20.43 | 6.57% | 4.73% | -18.21% | -50.94% | |
66 Neutral | $1.84B | 49.06 | 7.83% | ― | 48.87% | ― | |
64 Neutral | $4.30B | 999.30 | ― | ― | 9.50% | ― | |
62 Neutral | $4.42B | 34.85 | ― | ― | -0.25% | ― | |
55 Neutral | $2.76B | -143.13 | -1.86% | ― | 4.54% | -130.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.96B | -38.01 | -0.65% | 8.48% | -2.55% | 66.00% |
* Healthcare Sector Average
HYPMY
Hypera SA
4.84
1.64
51.31%
PRGO
Perrigo Company
14.32
-9.43
-39.70%
SUPN
Supernus Pharmaceuticals
48.78
8.78
21.95%
ANIP
ANI Pharmaceuticals
80.00
21.41
36.54%
INDV
Indivior
35.00
23.60
207.02%
AMRX
Amneal Pharmaceuticals
14.19
6.20
77.60%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.